Anti-NMDA receptor encephalitis
MONDO:0021081An autoimmune acute encephalitis caused by antibodies against the glutamate NMDA receptor. It usually affects females and in the majority of cases it is associated with the presence of a tumor, most commonly an ovarian teratoma. The presence of a tumor in patients with this form of encephalitis implies that the latter is a paraneoplastic syndrome. It is manifested with psychiatric symptoms and epileptic seizures. It is a potentially lethal disorder; however, it is usually reversible with the prompt removal of the tumor.
Also known as: anti-NMDA receptor encephalitis, limbic encephalitis with N-methyl-D-aspartate receptor antibodies, limbic encephalitis with NMDA receptor antibodies
26 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New combo therapy targets Brain-Attacking antibodies in severe encephalitis
Disease control Recruiting nowThis study tests whether combining two drugs—ofatumumab and daratumumab—can safely and effectively treat people with severe anti-NMDAR autoimmune encephalitis, a condition where the immune system attacks the brain. The drugs aim to eliminate the harmful immune cells producing the…
Phase: PHASE3 • Sponsor: The First People's Hospital of Changzhou • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug trial aims to tame rare brain inflammation
Disease control Recruiting nowThis Phase 3 trial tests satralizumab, an injected drug, in 120 people with NMDAR or LGI1 encephalitis—rare conditions where the immune system attacks the brain. The goal is to see if the drug improves disability and reduces the need for rescue treatments. Participants receive ei…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug aims to block Brain-Attacking autoantibodies
Disease control Recruiting nowThis Phase 2a trial tests a drug called ART5803 in 30 adults with anti-NMDAR encephalitis or related psychiatric disease. The drug is a lab-made antibody designed to block harmful autoantibodies from attacking brain receptors. The study focuses on safety and tolerability, with ea…
Phase: PHASE2 • Sponsor: Arialys Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New PET tracer aims to reveal hidden inflammation in cancer patients
Diagnosis Recruiting nowThis early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Computer alert aims to stop deadly clots after hospital stay
Prevention Recruiting nowThis study tests whether a computer alert can help doctors remember to prescribe blood-thinning medicine for high-risk patients after they leave the hospital. Blood clots are a serious risk for some hospitalized patients, even after discharge. The trial will include 400 adults ag…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 09:07 UTC
-
Scientists track prednisolone levels to improve dosing for inflammatory conditions
Knowledge-focused Recruiting nowThis pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Hunting for hidden antibodies in brain inflammation
Knowledge-focused Recruiting nowThis study aims to better understand autoimmune encephalitis, a condition where the immune system attacks the brain. Researchers will analyze blood and spinal fluid from 20 patients to find new antibodies that may explain the disease in people who currently test negative. The goa…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
When to boost? new trial seeks best COVID-19 shot timing for vulnerable patients
Knowledge-focused Recruiting nowThis study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…
Phase: PHASE3 • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Life after brain inflammation: new study probes hidden scars of rare disease
Knowledge-focused Recruiting nowThis study looks at the long-term social and emotional challenges faced by people who have had NMDA receptor encephalitis, a rare brain inflammation. Researchers will ask 30 adults to complete questionnaires about fatigue, anxiety, depression, sleep, and quality of life. The goal…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC